Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin

progesterone induced blocking factor

  • You have access
    New Insights as to Why Progesterone Receptor Modulators, such as Mifepristone, Seem to Be More Effective in Treating Cancers that Are Devoid of the Classical Nuclear Progesterone Receptor
    JEROME H. CHECK and DIANE CHECK
    Anticancer Research December 2021, 41 (12) 5873-5880; DOI: https://doi.org/10.21873/anticanres.15407
  • You have access
    Palliative Benefits of Oral Mifepristone for the Treatment of Metastatic Fibroblastic Osteosarcoma
    JEROME H. CHECK, DIANE CHECK, TRINA PORETTA and CARRIE WILSON
    Anticancer Research April 2021, 41 (4) 2111-2115; DOI: https://doi.org/10.21873/anticanres.14982
  • You have access
    Treatment With Mifepristone Allows a Patient With End-stage Pancreatic Cancer in Hospice on a Morphine Drip to Restore a Decent Quality of Life
    JEROME H. CHECK, DIANE CHECK, MAYA D. SRIVASTAVA, TRINA PORETTA and JAMES K. AIKINS
    Anticancer Research December 2020, 40 (12) 6997-7001; DOI: https://doi.org/10.21873/anticanres.14724
  • You have access
    Therapy Aimed to Suppress the Production of the Immunosuppressive Protein Progesterone Induced Blocking Factor (PIBF) May Provide Palliation and/or Increased Longevity for Patients With a Variety of Different Advanced Cancers – A Review
    JEROME H. CHECK and DIANE CHECK
    Anticancer Research July 2019, 39 (7) 3365-3372; DOI: https://doi.org/10.21873/anticanres.13479
  • You have access
    Mifepristone Extends Both Length and Quality of Life in a Patient With Advanced Non-small Cell Lung Cancer that Has Progressed Despite Chemotherapy and a Check-point Inhibitor
    JEROME H. CHECK, DIANE CHECK and TRINA PORETTA
    Anticancer Research April 2019, 39 (4) 1923-1926; DOI: https://doi.org/10.21873/anticanres.13301
Anticancer Research

© 2025 Anticancer Research

Powered by HighWire